Intellia’s High‑Beta Surge: Big Alpha Amid a Storm of Risk Flags

Why the biotech’s aggressive upside could be offset by deep drawdowns in the next 12‑18 months

NTLA Intellia Therapeutics, Inc.

In this report

01

Returns Overview

Period returns, alpha, cumulative performance, distributions

P. 2-3

→

02

Volatility Analysis

Annualized volatility, downside deviation, drawdowns

P. 4-5

→

03

Beta & Correlation

Trailing, upside, downside beta, systematic risk

P. 6-7

→

04

Risk-Adjusted Returns

Sharpe, Sortino, Calmar, Information, Treynor

P. 8-9

→

05

Market Regime Analysis

Bull/bear behavior, capture ratios

P. 10-11

→

06

Investment Highlights & Risk Summary

Executive summary, risk flags, rankings

P. 12-13

→

Returns Overview

Intellia Therapeutics, Inc. (NTLA) — Return Performance

Intellia Therapeutics (NTLA) displayed a mixed return profile across horizons, delivering strong upside in the medium term but significant underperformance over longer intervals. The stock posted a 50.61% gain over six months, outpacing its sector ETF by 42.75 percentage points, yet it lagged sharply on a two‑year basis with a -39.5% return versus -74.72% for the sector, indicating a narrower relative decline in that period.

Period Returns vs S&P 500 & XLV

Monthly Returns Heatmap

NTLA

Short‑term (1M) performance was negative at -3.77%, underperforming the sector by 1.18 percentage points, but the three‑month return turned positive at 5.62% while still trailing the sector by 7.48 points. The six‑month and one‑year windows show robust outperformance, delivering +50.61% and +44.35% respectively versus sector gains of +51.77% and +29.82%, highlighting a strong rebound after recent weakness.

Returns Overview

Intellia Therapeutics, Inc. (NTLA) — Return Charts

Volatility Analysis

Intellia Therapeutics, Inc. (NTLA) — Volatility Profile

Intellia Therapeutics (NTLA) exhibits markedly higher price variability than the broader market, with an annualized volatility of 78.3% compared to the S&P 500's 17.8%, indicating more than four times the typical daily swing. The stock’s downside profile is severe: a downside deviation of 50.95% and a historic maximum drawdown of -96.45% over a multi‑year period demonstrate that losses can be deep and prolonged, with no recovery to prior peaks as of the latest data point. While short‑term volatility (60‑day at 76.6%) remains close to the long‑term average, the 252‑day figure of 96.6% exceeds the annualized level, suggesting an upward bias in recent risk exposure.

Volatility Metrics

NTLA

The volatility of NTLA is substantially above the S&P 500 benchmark, reflecting its biotech sector dynamics and limited operating history. Downside risk metrics are pronounced: a downside deviation of 50.95% signals that negative returns dominate a large share of price movements, while the -96.45% max drawdown—spanning from September 2021 to April 2025 with no recovery—highlights extreme tail‑risk and long duration. The current 60‑day volatility (76.6%) is marginally lower than the 252‑day volatility (96.6%), indicating that recent price swings have softened relative to the heightened risk observed over the past year, yet remain well above the company’s own long‑term average of roughly 78%.

NTLA's annualized volatility is more than four times higher than the S&P 500.
Downside deviation exceeds 50%, pointing to a bias toward larger negative moves.
The maximum historical drawdown of -96.45% represents near‑total loss of value over a multi‑year horizon.
Recent 60‑day volatility is slightly lower than the 252‑day figure, suggesting a modest short‑term easing of risk.
No price recovery has occurred since the peak in September 2021, indicating prolonged downside exposure.

Positive Characteristics
Short‑term (60‑day) volatility has eased relative to the elevated 252‑day level, hinting at potential stabilization.
The stock's high volatility may offer opportunities for traders seeking large price moves, provided they accept substantial risk.

Volatility Analysis

Intellia Therapeutics, Inc. (NTLA) — Volatility & Drawdown Charts

Beta & Correlation

Intellia Therapeutics, Inc. (NTLA) — Beta Profile

Intellia Therapeutics exhibits a trailing beta of 1.78 versus the S&P 500, placing it firmly in the aggressive category (>1.2). This indicates that the stock tends to amplify broad market movements by roughly 78%, making it more volatile than the overall market. The upside beta of 1.43 and downside beta of 1.62 reveal a modest asymmetry: the share is slightly less responsive on upward moves but more sensitive when markets decline, a pattern that heightens downside risk for defensive investors. With an R-squared of 0.168 (correlation 0.41) against the market, only about 17% of the stock’s variance is explained by broader equity trends, leaving roughly 83% driven by idiosyncratic factors and underscoring limited diversification benefit from a pure market exposure perspective. Comparing its market beta (1.78) to sector beta (1.716) against XLV shows that most of the systematic risk stems from healthcare‑sector dynamics, while the residual gap reflects company‑specific drivers.

Beta & Correlation Metrics

NTLA

The trailing market beta of 1.78 signals aggressive price behavior relative to the S&P 500, meaning investors should expect amplified swings in line with overall equity sentiment. The asymmetric beta—downside 1.621 versus upside 1.43—suggests a steeper reaction to negative market shocks, an important consideration for risk‑averse portfolios. A low R-squared (16.8%) and modest correlation (0.41) indicate that the majority of price movement is not captured by market factors, implying limited hedging benefit from broad equity diversification. Systematic risk accounts for 16.8% of total variance, while idiosyncratic risk dominates at 83.2%, highlighting the prominence of company‑specific catalysts such as clinical trial outcomes and regulatory news. The sector beta of 1.716, close to the market beta, shows that most systematic exposure is tied to healthcare sector trends rather than broader market forces.

Trailing beta of 1.78 classifies Intellia as an aggressive stock with amplified market sensitivity.
Downside beta (1.621) exceeds upside beta (1.43), indicating greater vulnerability to market declines.
R-squared of 16.8% means only a small fraction of price variance is explained by the S&P 500, limiting diversification benefits.
Systematic risk constitutes 16.8% of total volatility; idiosyncratic risk dominates at 83.2%, emphasizing company‑specific drivers.
Sector beta (1.716) is nearly equal to market beta, showing that most systematic exposure derives from healthcare sector movements.

Positive Characteristics
High upside beta of 1.43 still offers strong participation in bullish market phases.
Sector beta close to market beta suggests the stock captures favorable industry trends alongside broader market rallies.
Low correlation (0.41) with the S&P 500 provides potential portfolio diversification when combined with non‑healthcare assets.

Beta & Correlation

Intellia Therapeutics, Inc. (NTLA) — Rolling Beta

Positive Notes

High upside beta of 1.43 still offers strong participation in bullish market phases.

Sector beta close to market beta suggests the stock captures favorable industry trends alongside broader market rallies.

Low correlation (0.41) with the S&P 500 provides potential portfolio diversification when combined with non‑healthcare assets.

Risk-Adjusted Returns

Intellia Therapeutics, Inc. (NTLA) — Risk-Adjusted Performance

Intellia Therapeutics (NTLA) delivers modest risk‑adjusted returns, reflected in a Sharpe ratio of 0.283 that falls well below the benchmark threshold of 1.0 for attractive risk‑adjusted performance. The Sortino ratio of 0.435 exceeds the Sharpe figure, indicating that downside volatility is less pronounced than overall volatility and suggesting a relatively favorable asymmetry in return distribution. However, other metrics such as the Calmar (0.267) and Information (0.157) ratios signal limited upside relative to drawdown severity and only marginal alpha generation, respectively, while an elevated Treynor ratio of 12.446 points to strong excess returns per unit of systematic risk.

Risk-free rate: 3.63% (Fed Funds Rate)

Risk-Adjusted Metrics

NTLA

Intellia's Sharpe ratio of 0.283 signals that the stock’s total return barely compensates for its total volatility, implying a low reward‑for‑risk profile compared with market standards. The higher Sortino ratio (0.435) shows that downside risk is less severe than overall risk, which can be appealing to investors focused on capital preservation during market declines. Nevertheless, the Calmar ratio of 0.267 reflects a modest return relative to its worst historical drawdown, highlighting vulnerability to sharp price corrections. The Information ratio of 0.157 suggests only slight consistency in generating excess returns over a benchmark, falling short of the >0.5 level that denotes robust active management performance.

Sharpe ratio is well below 1.0, indicating weak risk‑adjusted return.
Sortino exceeds Sharpe, showing a more favorable downside risk profile.
Calmar ratio of 0.267 points to limited compensation for maximum drawdown severity.
Information ratio under 0.5 reflects marginal consistency in alpha generation.
Treynor ratio is high (12.446), suggesting strong excess return per unit of systematic risk.

Positive Characteristics
Higher Sortino than Sharpe indicates a comparatively gentle downside volatility.
Elevated Treynor ratio demonstrates effective compensation for market beta exposure.

Risk-Adjusted Returns

Intellia Therapeutics, Inc. (NTLA) — Rolling Sharpe & Sortino

Positive Notes

Higher Sortino than Sharpe indicates a comparatively gentle downside volatility.

Elevated Treynor ratio demonstrates effective compensation for market beta exposure.

Market Regime Analysis

Intellia Therapeutics, Inc. (NTLA) — Regime Behavior

Intellia Therapeutics (NTLA) exhibits markedly divergent performance across market regimes, reflecting its high beta and growth-oriented profile. In Bull-LowVol environments the stock delivers strong excess returns of 6.19% per month, driven by investor optimism and ample liquidity that amplify biotech valuations. Conversely, during Bull-HighVol periods the average monthly gain drops to 2.32%, indicating sensitivity to heightened market turbulence even when the broader index remains positive. In bear markets the security suffers pronounced declines, with a -17.34% average in Bear-LowVol months and a still severe -7.56% loss in Bear-HighVol months, underscoring its limited defensive characteristics.

Current Market Regime: Bull-HighVol

Bull-LowVol = calm uptrend • Bull-HighVol = volatile uptrend • Bear-LowVol = orderly decline • Bear-HighVol = crisis

Regime Returns & Capture Ratios

NTLA

The stock’s upside capture of 201.1% suggests it more than doubles the S&P 500's gains during rising markets, but a downside capture of 261.0% reveals that losses far exceed market declines in down periods, yielding a capture ratio of 0.77. This asymmetry signals high upside potential offset by considerable downside risk, especially relevant as the current regime is Bull-HighVol where NTLA’s average return contracts to 2.32% per month. Investors should therefore anticipate modest appreciation amid volatility and be prepared for amplified losses if market sentiment turns bearish.

Market Regime Analysis

Intellia Therapeutics, Inc. (NTLA) — Regime & Capture Charts

Regime Timeline

NTLA’s monthly returns are strongest in calm uptrends (6.19%) but weaken substantially when volatility rises (2.32%).
Downside capture of 261.0% indicates the stock loses more than two and a half times the market's decline during bear periods.
The capture ratio below 1.0 (0.77) reflects an imbalance: high upside capture is offset by disproportionately higher downside exposure.
In the current Bull-HighVol regime, NTLA’s performance is likely to be muted relative to its peak Bull-LowVol returns.

Positive Characteristics
Exceptionally high upside capture (201.1%) demonstrates strong participation in market rallies.
The stock still delivers positive average returns (+2.32% per month) even during volatile bullish phases, offering some upside despite heightened risk.

Investment Highlights & Risk Summary

Intellia Therapeutics, Inc. (NTLA) — Summary & Implications

Intellia Therapeutics delivered a robust 1‑year total return of 44.35%, generating an alpha of 25.35% versus the S&P 500 and outperforming its healthcare sector benchmark XLV by 29.82%. However, this outperformance comes with pronounced risk characteristics: annualized volatility of 78.3%, a beta of 1.78, and a historic maximum drawdown of –96.45% indicate that the stock is highly sensitive to market swings and has experienced near‑total loss periods. The upside capture ratio of 201.1% suggests that the company participates strongly in market rallies, yet the downside capture of 261.0% and a Sharpe ratio of only 0.283 reveal that losses are amplified far more than gains on a risk‑adjusted basis. For investors willing to tolerate elevated volatility and deep drawdowns, NTLA offers significant upside potential; for more risk‑averse capital, the asymmetrical risk profile may be prohibitive.

Summary Dashboard

Investment Highlights

1Y absolute return of 44.35% reflects strong recent momentum in the gene‑editing space.
Alpha of 25.35% versus the S&P 500 and sector alpha of 29.82% demonstrate that NTLA has outperformed both broad market and healthcare peers on a risk‑adjusted basis.
Upside capture of 201.1% indicates the stock more than doubles its gains when the broader market rises, providing attractive participation in bullish regimes.
Beta of 1.78 shows heightened sensitivity to market movements, which can translate into amplified upside during strong equity rallies.

Risk-Return Rankings

NTLA HIGH

High‑return, high‑volatility biotech with outsized upside capture but severe downside risk.

Strength: Strong relative alpha (+25.35% vs S&P 500) and sector outperformance (+29.82%).

Concern: Extreme drawdown history (-96.45%) and low Sharpe (0.283) signal poor risk‑adjusted performance.

Key Takeaways

Intellia’s return profile is driven by speculative biotech catalysts rather than stable cash flow.
The stock’s volatility (78.3%) and beta (1.78) make it more reactive than the broader market, amplifying both gains and losses.
Downside capture of 261% means that in market declines, NTLA loses roughly two‑and‑a‑half times what the S&P 500 loses.
Risk‑adjusted metrics such as Sharpe (0.283) and Sortino (0.435) are well below conventional thresholds (>1.0), indicating modest compensation for risk taken.

PORTFOLIO IMPLICATIONS

NTLA may serve as a high‑convexity satellite within a diversified equity portfolio, offering potential alpha when biotech pipelines de‑risk or regulatory approvals materialize. Its elevated beta and downside capture suggest it should be limited to a small allocation (e.g., <5% of total assets) for investors with sufficient risk tolerance. Pairing NTLA with lower‑beta, higher‑Sharpe holdings can help smooth overall portfolio volatility while preserving the upside exposure that gene‑editing breakthroughs could provide.

NTLA

Related Reports

Visit finexus.net/reports for more reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.